Litcius/Paper detail

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy

Yuheng Hu, Ye Zeng, Fei Wang, Yi Qin, Xiaowu Xu, Xianjun Yu, Shunrong Ji

2021Frontiers in Endocrinology56 citationsDOIOpen Access PDF

Abstract

Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely expressed in NENs, are G-protein coupled receptors that can be activated by somatostatins or its synthetic analogs. Therefore, SSTRs have been widely researched as a diagnostic marker and therapeutic target in pNETs. A large number of studies have demonstrated the clinical significance of SSTRs in pNETs. In this review, relevant literature has been appraised to summarize the most recent empirical evidence addressing the clinical significance of SSTRs in pNETs. Overall, these studies have shown that SSTRs have great value in the diagnosis, treatment, and prognostic prediction of pNETs; however, further research is still necessary.

Topics & Concepts

Neuroendocrine tumorsSomatostatin receptorSomatostatinMedicineOctreotideSomatostatin receptor 2OncologyInternal medicineCancer researchNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments
Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy | Litcius